SCHEMBL315329

SCHEMBL315329

C[CH]c1c[nH]c2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.64
IMPDH2 P12268 1/20 0.64
HPGD P15428 3/20 0.58
HTT P42858 1/20 0.58
PTGS2 P35354 3/20 0.57
ATM Q13315 1/20 0.54
APP P05067 1/20 0.53
MAPT P10636 4/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
LMNA P02545 3/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
USP2 O75604 2/20 0.51
SENP7 Q9BQF6 2/20 0.50
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27821745 0.86 CYP2A6 (0.69) CYP2A6IMPDH2HPGDHTTPTGS2
SCHEMBL7275100 0.83 CYP2A6 (0.60) CYP2A6IMPDH2HPGDHTTPTGS2
SCHEMBL13083133 0.83 CYP2A6 (0.60) CYP2A6IMPDH2HPGDHTTPTGS2
SCHEMBL10489040 0.82 CYP2A6 (0.69) CYP2A6IMPDH2HPGDHTTATM
SCHEMBL3621033 0.79 CYP2A6 (0.60) CYP2A6IMPDH2HPGDHTTPTGS2
SCHEMBL7370729 0.79 SIRT2 (0.46) CYP2A6IMPDH2HPGDHTTATM
SCHEMBL14161292 0.79 CYP2A6 (0.55) CYP2A6IMPDH2HPGDHTTPTGS2
SCHEMBL19889385 0.79 CYP2A6 (0.55) CYP2A6IMPDH2HPGDHTTPTGS2
3-Formylindole SCHEMBL19180195 0.78 CYP2A6 (0.70) CYP2A6IMPDH2HPGDHTTPTGS2
3-Formylindole SCHEMBL56373 0.78 CYP2A6 (1.00) CYP2A6IMPDH2HPGDHTTAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112624955-B Separation method of 3-indoloethyl (3 '-methyl-2' -ketone) valeramide 西北农林科技大学 2024-07-09 CN claimed
US-20240207253-A1 Inhibitors of CDR1 for Reversal of Azole Drug Resistance in Fungal Infections THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2024-06-27 US claimed
CN-113292430-B Alpha-carbonyl alkenyl ester compound and preparation method and application thereof 江西师范大学 2022-11-29 CN claimed
EP-3523316-B1 MELANOCORTIN-1-RECEPTOR AGONISTS DSM IP ASSETS BV (NL) 2021-11-03 EP claimed
US-20210277058-A1 MELANOCORTIN-1-RECEPTOR AGONISTS DSM IP ASSETS B.V. (NL) 2021-09-09 US claimed
CN-113292430-A Alpha-carbonyl alkenyl ester compound and preparation method and application thereof 江西师范大学 2021-08-24 CN claimed
CN-112624955-A Separation method of 3-indolylethyl (3 '-methyl-2' -ketone) valeramide 西北农林科技大学 2021-04-09 CN claimed
EP-3692978-A1 NOVEL METHOD DSM IP Assets B.V. (NL) 2020-08-12 EP claimed
CN-111344013-A Use of NOX inhibitors for the treatment of cancer 吉恩基奥泰克斯瑞士股份有限公司 2020-06-26 CN claimed
CN-106397254-A Chiral 8-hydroxyhomodrimane sesquiterpene amide compound and application of same as agricultural bactericide 南京农业大学 2017-02-15 CN claimed
EP-0357316-A1 Antidepressant N-substituted nicotinamide compounds PFIZER INC. (US) 1990-03-07 EP claimed
EP-0181152-B1 PIPERAZINE COMPOUND AS PAF-ANTAGONIST FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-09-13 EP claimed
US-4861891-A Antidepressant N-substituted nicotinamide compounds PFIZER INC. (US) 1989-08-29 US claimed
EP-0251194-A1 Use of carbocyclic and heterocyclic condensed dihydropyridines for the preparation of cardioprotective remedies and heterocyclic and carbocyclic condensed dihydropyridines and methods and intermediates for their preparation BOEHRINGER INGELHEIM KG (DE) 1988-01-07 EP claimed
EP-0243122-A2 Piperazine compound as PAF-antagonist FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1987-10-28 EP claimed
EP-0230242-A2 Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their use HOECHST AKTIENGESELLSCHAFT (DE) 1987-07-29 EP claimed
EP-0181152-A1 Piperazine compound as PAF-antagonist FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-05-14 EP claimed
US-4563464-A 2-Azabicyclo(2.2.2)octane derivatives and their use as immunosuppressive agents RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1986-01-07 US claimed
US-4528293-A Heteroaromatic derivatives of iminomethyl piperidines and use to inhibit gastric acid secretion MCNEILAB, INC. (US) 1985-07-09 US claimed
US-4199512-A Compounds for alleviating hypertension E. R. SQUIBB & SONS, INC. (US) 1980-04-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210277058-A1 MELANOCORTIN-1-RECEPTOR AGONISTS MC1R, MC3R, MC5R CYP2A6 4564/4885IMPDH2 4610/4885HPGD 1765/4885
US-20240207253-A1 Inhibitors of CDR1 for Reversal of Azole Drug Resistance in Fungal Infections ABCC1, ABCC2, ERG28 CYP2A6 1565/4885IMPDH2 2781/4885HPGD 4799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.